{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:20:03Z","timestamp":1792448403845,"version":"4.5.0"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40263-026-01296-7","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:14:34Z","timestamp":1778926474000},"page":"949-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Predictors of Antidepressant Effects of Ketamine and Esketamine in Treatment-Resistant Unipolar and Bipolar Depression: A Systematic Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-5223","authenticated-orcid":false,"given":"Omer A.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentyn","family":"Sobolenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ishrat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Lipsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"15","key":"1296_CR1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.2017.3826","volume":"317","author":"MJ Friedrich","year":"2017","unstructured":"Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317(15):1517. https:\/\/doi.org\/10.1001\/jama.2017.3826.","journal-title":"JAMA"},{"key":"1296_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","volume":"242","author":"KM Johnston","year":"2019","unstructured":"Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195\u2013210. https:\/\/doi.org\/10.1016\/j.jad.2018.06.045.","journal-title":"J Affect Disord"},{"issue":"1","key":"1296_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01738-y","volume":"9","author":"L Cui","year":"2024","unstructured":"Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9(1):30. https:\/\/doi.org\/10.1038\/s41392-024-01738-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1296_CR4","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry. 2006;163(11):1905\u201317. https:\/\/doi.org\/10.1176\/ajp.2006.163.11.1905.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1296_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment\u2010resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120.","journal-title":"World Psychiatry"},{"issue":"1","key":"1296_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1192\/bjp.bp.110.086983","volume":"200","author":"CT Li","year":"2012","unstructured":"Li CT, Bai YM, Huang YL, Chen YS, Chen TJ, Cheng JY, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012;200(1):45\u201351. https:\/\/doi.org\/10.1192\/bjp.bp.110.086983.","journal-title":"Br J Psychiatry"},{"issue":"9","key":"1296_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/07067437241245384","volume":"69","author":"RW Lam","year":"2024","unstructured":"Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. R\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (CANMAT) 2023: mise \u00e0 jour des lignes directrices cliniques pour la prise en charge du trouble d\u00e9pressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641\u201387. https:\/\/doi.org\/10.1177\/07067437241245384.","journal-title":"Can J Psychiatry"},{"key":"1296_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1557","volume":"378","author":"T Kendrick","year":"2022","unstructured":"Kendrick T, Pilling S, Mavranezouli I, Megnin-Viggars O, Ruane C, Eadon H, et al. Management of depression in adults: summary of updated NICE guidance. BMJ. 2022;378:o1557. https:\/\/doi.org\/10.1136\/bmj.o1557.","journal-title":"BMJ"},{"issue":"4","key":"1296_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351\u20134. https:\/\/doi.org\/10.1016\/S0006-3223(99)00230-9.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1296_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250\u20136. https:\/\/doi.org\/10.1016\/j.biopsych.2012.06.022.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1296_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","volume":"176","author":"JL Phillips","year":"2019","unstructured":"Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176(5):401\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18070834.","journal-title":"Am J Psychiatry"},{"issue":"25","key":"1296_CR12","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","volume":"388","author":"A Anand","year":"2023","unstructured":"Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2302399.","journal-title":"N Engl J Med"},{"key":"1296_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2023.04.141","volume":"335","author":"TM Hietamies","year":"2023","unstructured":"Hietamies TM, McInnes LA, Klise AJ, Worley MJ, Qian JJ, Williams LM, et al. The effects of ketamine on symptoms of depression and anxiety in real-world care settings: a retrospective controlled analysis. J Affect Disord. 2023;335:484\u201392. https:\/\/doi.org\/10.1016\/j.jad.2023.04.141.","journal-title":"J Affect Disord"},{"issue":"2","key":"1296_CR14","first-page":"2","volume":"16","author":"R Rahrig","year":"2025","unstructured":"Rahrig R, Kosikowski K, Whyde H, Devoll K, Honigford A, Davis M, et al. Spravato\u00ae FDA-approved as monotherapy for adults with treatment-resistant depression. Pharm Wellness Rev. 2025;16(2):2.","journal-title":"Pharm Wellness Rev."},{"issue":"2","key":"1296_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/104012371202400104","volume":"66","author":"J Swainson","year":"2021","unstructured":"Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations du groupe de travail du r\u00e9seau canadien pour les traitements de l\u2019humeur et de l\u2019anxi\u00e9t\u00e9 (canmat) concernant l\u2019utilisation de la k\u00e9tamine rac\u00e9mique chez les adultes souffrant de trouble d\u00e9pressif majeur. Can J Psychiatry. 2021;66(2):113\u201325. https:\/\/doi.org\/10.1177\/104012371202400104.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"1296_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyad065","volume":"27","author":"J Ekstrand","year":"2024","unstructured":"Ekstrand J, Takamiya A, Nordenskjold A, Kirov G, Sienaert P, Kellner CH, et al. Ketamine or ECT? What have we learned from the KetECT and ELEKT-D trials? Int J Neuropsychopharmacol. 2024;27(1):pyad065. https:\/\/doi.org\/10.1093\/ijnp\/pyad065.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"1296_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","volume":"79","author":"TG Rhee","year":"2022","unstructured":"Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis. JAMA Psychiat. 2022;79(12):1162\u201372. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3352.","journal-title":"JAMA Psychiat"},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2024.11.034","volume":"371","author":"ZM Shi","year":"2025","unstructured":"Shi ZM, Lan XJ, Chen Q, Chen JJ, Su ZA, Huang XB, et al. Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: a meta-analysis of randomized controlled trials. J Affect Disord. 2025;371:45\u201353. https:\/\/doi.org\/10.1016\/j.jad.2024.11.034.","journal-title":"J Affect Disord"},{"issue":"2","key":"1296_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1192\/bjp.2025.10472","volume":"228","author":"A Jelovac","year":"2026","unstructured":"Jelovac A, Braithwaite R, McLoughlin DM. Advancing ketamine in the treatment hierarchy for refractory depression: commentary, Jelovac et al. Br J Psychiatry. 2026;228(2):174\u20135. https:\/\/doi.org\/10.1192\/bjp.2025.10472.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"1296_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1176\/appi.focus.20240040","volume":"23","author":"SI Elliott","year":"2025","unstructured":"Elliott SI, Katz BR, Ostroff BR, Ansari M, Holmes SE, Sanacora G. Ketamine versus electroconvulsive therapy for the treatment of depression: a guide for clinicians. Focus. 2025;23(2):195\u2013205. https:\/\/doi.org\/10.1176\/appi.focus.20240040.","journal-title":"Focus"},{"issue":"12","key":"1296_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1176\/appi.ajp.2010.09111680","volume":"167","author":"GE Simon","year":"2010","unstructured":"Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry. 2010;167(12):1445\u201355. https:\/\/doi.org\/10.1176\/appi.ajp.2010.09111680.","journal-title":"Am J Psychiatry"},{"key":"1296_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.650318","volume":"12","author":"R Deif","year":"2021","unstructured":"Deif R, Salama M. Depression from a precision mental health perspective: utilizing personalized conceptualizations to guide personalized treatments. Front Psychiatry. 2021;12:650318. https:\/\/doi.org\/10.3389\/fpsyt.2021.650318.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1296_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01523-3","volume":"8","author":"BS Wade","year":"2025","unstructured":"Wade BS, Pindale R, Luccarelli J, Li S, Meisner RC, Seiner SJ, et al. Prediction of individual treatment allocation between electroconvulsive therapy or ketamine using the Personalized Advantage Index. NPJ Digit Med. 2025;8(1):127. https:\/\/doi.org\/10.1038\/s41746-025-01523-3.","journal-title":"NPJ Digit Med"},{"issue":"12","key":"1296_CR24","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","volume":"27","author":"RB Price","year":"2022","unstructured":"Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators. Mol Psychiatry. 2022;27(12):5096\u2013112. https:\/\/doi.org\/10.1038\/s41380-022-01757-7.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"1296_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40473-024-00286-7","volume":"11","author":"A Baminiwatta","year":"2024","unstructured":"Baminiwatta A, Menon V. Predictors of response to electroconvulsive therapy in major depressive disorder: a review of recent research findings. Curr Behav Neurosci Rep. 2024;11(4):211\u201322. https:\/\/doi.org\/10.1007\/s40473-024-00286-7.","journal-title":"Curr Behav Neurosci Rep"},{"key":"1296_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neulet.2016.10.047","volume":"669","author":"M Pinna","year":"2018","unstructured":"Pinna M, Manchia M, Oppo R, Scano F, Pillai G, Loche AP, et al. Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review. Neurosci Lett. 2018;669:32\u201342. https:\/\/doi.org\/10.1016\/j.neulet.2016.10.047.","journal-title":"Neurosci Lett"},{"issue":"5","key":"1296_CR27","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/s41380-024-02803-2","volume":"30","author":"D Loef","year":"2025","unstructured":"Loef D, Hoogendoorn AW, Somers M, Mocking RJ, Scheepens DS, Scheepstra KW, et al. A prediction model for electroconvulsive therapy effectiveness in patients with major depressive disorder from the Dutch ECT Consortium (DEC). Mol Psychiatry. 2025;30(5):1915\u201324. https:\/\/doi.org\/10.1038\/s41380-024-02803-2.","journal-title":"Mol Psychiatry"},{"key":"1296_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/NDT.S388164","volume":"19","author":"F Gonterman","year":"2023","unstructured":"Gonterman F. A systematic review assessing patient-related predictors of response to transcranial magnetic stimulation in major depressive disorder. Neuropsychiatr Dis Treat. 2023;19:565\u201377. https:\/\/doi.org\/10.2147\/NDT.S388164.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"1296_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15040771","volume":"15","author":"C Rong","year":"2018","unstructured":"Rong C, Park C, Rosenblat JD, Subramaniapillai M, Zuckerman H, Fus D, et al. Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Public Health. 2018;15(4):771. https:\/\/doi.org\/10.3390\/ijerph15040771.","journal-title":"Int J Environ Res Public Health"},{"key":"1296_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116355","volume":"345","author":"JL Constantino","year":"2025","unstructured":"Constantino JL, Godschalk M, van Dalfsen JH, Veraart JK, Spijker J, van Exel E, et al. Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: a systematic review. Psychiatry Res. 2025;345:116355. https:\/\/doi.org\/10.1016\/j.psychres.2025.116355.","journal-title":"Psychiatry Res"},{"key":"1296_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"8","key":"1296_CR32","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856\u201364. https:\/\/doi.org\/10.1001\/archpsyc.63.8.856.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1296_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","volume":"65","author":"LE Phelps","year":"2009","unstructured":"Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65(2):181\u20134. https:\/\/doi.org\/10.1016\/j.biopsych.2008.09.029.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"1296_CR34","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793\u2013802. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.90.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1296_CR35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.pnpbp.2011.03.019","volume":"35","author":"L Ibrahim","year":"2011","unstructured":"Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, et al. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1155\u20139. https:\/\/doi.org\/10.1016\/j.pnpbp.2011.03.019.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"1296_CR36","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/bdi.12003","volume":"14","author":"DA Luckenbaugh","year":"2012","unstructured":"Luckenbaugh DA, Ibrahim L, Brutsche N, Franco\u2010Chaves J, Mathews D, Marquardt CA, et al. Family history of alcohol dependence and antidepressant response to an N\u2010methyl\u2010D\u2010aspartate antagonist in bipolar depression. Bipolar Disord. 2012;14(8):880\u20137. https:\/\/doi.org\/10.1111\/bdi.12003.","journal-title":"Bipolar Disord"},{"issue":"9","key":"1296_CR37","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.14m09049","volume":"75","author":"DF Ionescu","year":"2014","unstructured":"Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):5470. https:\/\/doi.org\/10.4088\/jcp.14m09049.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1296_CR38","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/bdi.12277","volume":"17","author":"DF Ionescu","year":"2014","unstructured":"Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA Jr. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2014;17(4):438\u201343. https:\/\/doi.org\/10.1111\/bdi.12277.","journal-title":"Bipolar Disord"},{"issue":"12","key":"1296_CR39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","volume":"76","author":"KA Lapidus","year":"2014","unstructured":"Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970\u20136. https:\/\/doi.org\/10.1016\/j.biopsych.2014.03.026.","journal-title":"Biol Psychiatry"},{"key":"1296_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","volume":"159","author":"DA Luckenbaugh","year":"2014","unstructured":"Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014;159:56\u201361. https:\/\/doi.org\/10.1016\/j.jad.2014.02.017.","journal-title":"J Affect Disord"},{"key":"1296_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00213-013-3255-x","volume":"231","author":"JW Murrough","year":"2015","unstructured":"Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology. 2015;231:481\u20138. https:\/\/doi.org\/10.1007\/s00213-013-3255-x.","journal-title":"Psychopharmacology"},{"issue":"5","key":"1296_CR42","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/npp.2014.298","volume":"40","author":"JW Murrough","year":"2014","unstructured":"Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2014;40(5):1084\u201390. https:\/\/doi.org\/10.1038\/npp.2014.298.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1296_CR43","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.13m08698","volume":"75","author":"MJ Niciu","year":"2014","unstructured":"Niciu MJ, Ionescu DALDF, Guevara S, Machado-Vieira R, Richards EM, Brutsche NE, et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014;75(5):2921. https:\/\/doi.org\/10.4088\/jcp.13m08698.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1296_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu039","volume":"18","author":"MJ Niciu","year":"2014","unstructured":"Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, et al. Ketamine\u2019s antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol. 2014;18(1):pyu039. https:\/\/doi.org\/10.1093\/ijnp\/pyu039.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1296_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.12740\/PP\/21175","volume":"48","author":"A Permoda-Osip","year":"2014","unstructured":"Permoda-Osip A, Skibinska M, Bartkowska-Sniatkowska A, Kliwicki S, Chlopocka-Wozniak M, Rybakowski JK. Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr Pol. 2014;48(1):35\u201347. https:\/\/doi.org\/10.12740\/PP\/21175.","journal-title":"Psychiatr Pol"},{"issue":"11","key":"1296_CR46","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1017\/s1461145714001011","volume":"17","author":"PR Shiroma","year":"2014","unstructured":"Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805\u201313. https:\/\/doi.org\/10.1017\/s1461145714001011.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"1296_CR47","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1176\/appi.neuropsych.14100243","volume":"27","author":"PR Shiroma","year":"2015","unstructured":"Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. The effect of repeated ketamine infusion over facial emotion recognition in treatment-resistant depression: a preliminary report. J Neuropsychiatry Clin Neurosci. 2015;27(4):362\u20134. https:\/\/doi.org\/10.1176\/appi.neuropsych.14100243.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1296_CR48","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jad.2016.10.026","volume":"208","author":"SJ Pennybaker","year":"2017","unstructured":"Pennybaker SJ, Niciu MJ, Luckenbaugh DA, Zarate CA. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. J Affect Disord. 2017;208:560\u20136. https:\/\/doi.org\/10.1016\/j.jad.2016.10.026.","journal-title":"J Affect Disord"},{"issue":"2","key":"1296_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/13651501.2017.1297834","volume":"21","author":"JK Rybakowski","year":"2017","unstructured":"Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Practice. 2017;21(2):99\u2013103. https:\/\/doi.org\/10.1080\/13651501.2017.1297834.","journal-title":"Int J Psychiatry Clin Practice"},{"issue":"7","key":"1296_CR50","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2018","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018;25(7):1592\u2013603. https:\/\/doi.org\/10.1038\/s41380-018-0256-5.","journal-title":"Mol Psychiatry"},{"key":"1296_CR51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jad.2018.02.049","volume":"232","author":"MJ Niciu","year":"2018","unstructured":"Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord. 2018;232:310\u20135. https:\/\/doi.org\/10.1016\/j.jad.2018.02.049.","journal-title":"J Affect Disord"},{"issue":"10","key":"1296_CR52","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1177\/0269881118793104","volume":"32","author":"RK Thomas","year":"2018","unstructured":"Thomas RK, Baker G, Lind J, Dursun S. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. J Psychopharmacol. 2018;32(10):1110\u20137. https:\/\/doi.org\/10.1177\/0269881118793104.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1296_CR53","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/jcp.0000000000000960","volume":"38","author":"S Vidal","year":"2018","unstructured":"Vidal S, Gex-Fabry M, Bancila V, Michalopoulos G, Warrot D, Jermann F, et al. Efficacy and safety of a rapid intravenous injection of ketamine 0.5 mg\/kg in treatment-resistant major depression: an open 4-week longitudinal study. J Clin Psychopharmacol. 2018;38(6):590\u20137. https:\/\/doi.org\/10.1097\/jcp.0000000000000960.","journal-title":"J Clin Psychopharmacol"},{"key":"1296_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","volume":"106","author":"W Zheng","year":"2018","unstructured":"Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res. 2018;106:61\u20138. https:\/\/doi.org\/10.1016\/j.jpsychires.2018.09.013.","journal-title":"J Psychiatr Res"},{"issue":"10","key":"1296_CR55","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1177\/0269881118798614","volume":"32","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Zheng W, Liu W, Wang C, Zhan Y, Li H, et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol. 2018;32(10):1118\u201326. https:\/\/doi.org\/10.1177\/0269881118798614.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"1296_CR56","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.euroneuro.2019.02.005","volume":"29","author":"S Aust","year":"2019","unstructured":"Aust S, G\u00e4rtner M, Basso L, Otte C, Wingenfeld K, Chae WR, et al. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Eur Neuropsychopharmacol. 2019;29(4):529\u201338. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.02.005.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1296_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2019.08.012","volume":"259","author":"W Liu","year":"2019","unstructured":"Liu W, Zhou Y, Zheng W, Wang C, Zhan Y, Lan X, et al. Repeated intravenous infusions of ketamine: neurocognition in patients with anxious and nonanxious treatment-resistant depression. J Affect Disord. 2019;259:1\u20136. https:\/\/doi.org\/10.1016\/j.jad.2019.08.012.","journal-title":"J Affect Disord"},{"issue":"3","key":"1296_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030133","volume":"12","author":"B O\u2019Brien","year":"2019","unstructured":"O\u2019Brien B, Lijffijt M, Wells A, Swann AC, Mathew SJ. The impact of childhood maltreatment on intravenous ketamine outcomes for adult patients with treatment-resistant depression. Pharmaceuticals. 2019;12(3):133. https:\/\/doi.org\/10.3390\/ph12030133.","journal-title":"Pharmaceuticals"},{"issue":"6","key":"1296_CR59","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428\u201338. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1296_CR60","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.19l12852","volume":"80","author":"B Singh","year":"2019","unstructured":"Singh B, Bobo WV, Rasmussen KG, Stoppel CJ, Rico JA Jr, Schak KM, et al. The association between body mass index and remission rates in patients with treatment-resistant depression who received intravenous ketamine. J Clin Psychiatry. 2019;80(6):19l12852. https:\/\/doi.org\/10.4088\/jcp.19l12852.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1296_CR61","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/acps.13096","volume":"140","author":"C Wang","year":"2019","unstructured":"Wang C, Zhou Y, Zheng W, Liu W, Zhan Y, Li H, et al. Association between depression subtypes and response to repeated\u2010dose intravenous ketamine. Acta Psychiatr Scand. 2019;140(5):446\u201357. https:\/\/doi.org\/10.1111\/acps.13096.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"1296_CR62","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/0269881119827811","volume":"33","author":"W Zheng","year":"2019","unstructured":"Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. J Psychopharmacol. 2019;33(4):494\u2013501. https:\/\/doi.org\/10.1177\/0269881119827811.","journal-title":"J Psychopharmacol"},{"key":"1296_CR63","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jad.2018.12.005","volume":"246","author":"W Zheng","year":"2019","unstructured":"Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. J Affect Disord. 2019;246:241\u20137. https:\/\/doi.org\/10.1016\/j.jad.2018.12.005.","journal-title":"J Affect Disord"},{"key":"1296_CR64","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jpsychires.2020.06.012","volume":"130","author":"EE Acevedo-Diaz","year":"2020","unstructured":"Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Park L, et al. Can \u2018floating\u2019 predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. J Psychiatr Res. 2020;130:280\u20135. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.06.012.","journal-title":"J Psychiatr Res"},{"key":"1296_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00844","volume":"11","author":"V Andrashko","year":"2020","unstructured":"Andrashko V, Novak T, Brunovsky M, Klirova M, Sos P, Horacek J. The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Front Psychiatry. 2020;11:844. https:\/\/doi.org\/10.3389\/fpsyt.2020.00844.","journal-title":"Front Psychiatry"},{"issue":"6","key":"1296_CR66","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.20m13232","volume":"81","author":"MH Chen","year":"2020","unstructured":"Chen MH, Lin WC, Wu HJ, Bai YM, Li CT, Tsai SJ, et al. Happiness during low-dose ketamine infusion predicts treatment response: reexploring the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. J Clin Psychiatry. 2020;81(6):8100. https:\/\/doi.org\/10.4088\/jcp.20m13232.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1296_CR67","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1017\/s1092852920001194","volume":"26","author":"MH Chen","year":"2020","unstructured":"Chen MH, Lin WC, Wu HJ, Bai YM, Li CT, Tsai SJ, et al. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. CNS Spectr. 2020;26(4):362\u20137. https:\/\/doi.org\/10.1017\/s1092852920001194.","journal-title":"CNS Spectr"},{"issue":"1","key":"1296_CR68","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/jcp.0000000000001149","volume":"40","author":"RM Dale","year":"2020","unstructured":"Dale RM, Bryant KA, Thompson NR. Metabolic syndrome rather than body mass index is associated with treatment response to ketamine infusions. J Clin Psychopharmacol. 2020;40(1):75\u20139. https:\/\/doi.org\/10.1097\/jcp.0000000000001149.","journal-title":"J Clin Psychopharmacol"},{"key":"1296_CR69","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jad.2019.09.010","volume":"260","author":"RM Dale","year":"2020","unstructured":"Dale RM, Bryant KA, Finnegan N, Cromer K, Thompson NR, Altinay M, et al. The NEO-FFI domain of openness to experience moderates ketamine response in treatment resistant depression. J Affect Disord. 2020;260:323\u20138. https:\/\/doi.org\/10.1016\/j.jad.2019.09.010.","journal-title":"J Affect Disord"},{"issue":"3","key":"1296_CR70","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/jcp.0000000000001209","volume":"40","author":"MP Freeman","year":"2020","unstructured":"Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, et al. Body mass index as a moderator of treatment response to ketamine for major depressive disorder. J Clin Psychopharmacol. 2020;40(3):287\u201392. https:\/\/doi.org\/10.1097\/jcp.0000000000001209.","journal-title":"J Clin Psychopharmacol"},{"key":"1296_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00687","volume":"14","author":"G Hasler","year":"2020","unstructured":"Hasler G, Suker S, Schoretsanitis G, Mihov Y. Sustained improvement of negative self-schema after a single ketamine infusion: an open-label study. Front Neurosci. 2020;14:687. https:\/\/doi.org\/10.3389\/fnins.2020.00687.","journal-title":"Front Neurosci"},{"issue":"3","key":"1296_CR72","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1017\/s1092852920002102","volume":"27","author":"O Lipsitz","year":"2020","unstructured":"Lipsitz O, McIntyre RS, Rodrigues NB, Lee Y, Gill H, Subramaniapillai M, et al. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. CNS Spectr. 2020;27(3):322\u201330. https:\/\/doi.org\/10.1017\/s1092852920002102.","journal-title":"CNS Spectr"},{"key":"1296_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2020.03.048","volume":"271","author":"W Liu","year":"2020","unstructured":"Liu W, Zhou Y, Wang C, Zheng W, Zhan Y, Lan X, et al. Baseline insomnia as a predictor of antidepressant efficacy to repeated intravenous ketamine for unipolar and bipolar depression: a preliminary study. J Affect Disord. 2020;271:1\u20138. https:\/\/doi.org\/10.1016\/j.jad.2020.03.048.","journal-title":"J Affect Disord"},{"key":"1296_CR74","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","volume":"274","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Rodrigues NB, Lee Y, Lipsitz O, Subramaniapillai M, Gill H, et al. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord. 2020;274:903\u201310. https:\/\/doi.org\/10.1016\/j.jad.2020.05.088.","journal-title":"J Affect Disord"},{"issue":"3","key":"1296_CR75","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1017\/s1092852920002187","volume":"7","author":"NB Rodrigues","year":"2020","unstructured":"Rodrigues NB, Siegel A, Lipsitz O, Cha DS, Gill H, Nasri F, et al. Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation. CNS Spectr. 2020;7(3):315\u201321. https:\/\/doi.org\/10.1017\/s1092852920002187.","journal-title":"CNS Spectr"},{"key":"1296_CR76","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jad.2020.08.058","volume":"277","author":"PR Shiroma","year":"2020","unstructured":"Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, et al. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2020;277:470\u20137. https:\/\/doi.org\/10.1016\/j.jad.2020.08.058.","journal-title":"J Affect Disord"},{"issue":"1","key":"1296_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00897-0","volume":"10","author":"PR Shiroma","year":"2020","unstructured":"Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10(1):206. https:\/\/doi.org\/10.1038\/s41398-020-00897-0.","journal-title":"Transl Psychiatry"},{"issue":"6","key":"1296_CR78","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/jcp.0000000000001305","volume":"40","author":"S Vidal","year":"2020","unstructured":"Vidal S, Jermann F, Aubry JM, Richard-Lepouriel H, Kosel M. Effect of ketamine on rumination in treatment-resistant depressive patients. J Clin Psychopharmacol. 2020;40(6):607\u201310. https:\/\/doi.org\/10.1097\/jcp.0000000000001305.","journal-title":"J Clin Psychopharmacol"},{"key":"1296_CR79","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.10208","volume":"8","author":"W Zheng","year":"2020","unstructured":"Zheng W, Zhou YL, Wang CY, Lan XF, Zhang B, Yang MZ, et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study. PeerJ. 2020;8:e10208. https:\/\/doi.org\/10.7717\/peerj.10208.","journal-title":"PeerJ"},{"key":"1296_CR80","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jad.2020.01.001","volume":"264","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Liu W, Zheng W, Wang C, Zhan Y, Lan X, et al. Predictors of response to repeated ketamine infusions in depression with suicidal ideation: an ROC curve analysis. J Affect Disord. 2020;264:263\u201371. https:\/\/doi.org\/10.1016\/j.jad.2020.01.001.","journal-title":"J Affect Disord"},{"key":"1296_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2020.100053","volume":"3","author":"MG Barbosa","year":"2021","unstructured":"Barbosa MG, Sarin LM, Tuena MA, Del Sant LC, Nakahira C, Magalh\u00e3es EJM, et al. Heterogeneous trajectory of depressive symptoms after repeated subcutaneous esketamine injections. J Affect Disord Rep. 2021;3:100053. https:\/\/doi.org\/10.1016\/j.jadr.2020.100053.","journal-title":"J Affect Disord Rep"},{"key":"1296_CR82","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/ndt.s339090","volume":"17","author":"S Borentain","year":"2021","unstructured":"Borentain S, Williamson D, Turkoz I, Popova V, McCall WV, Mathews M, et al. Effect of sleep disturbance on efficacy of esketamine in treatment-resistant depression: findings from randomized controlled trials. Neuropsychiatr Dis Treat. 2021;17:3459\u201370. https:\/\/doi.org\/10.2147\/ndt.s339090.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"1296_CR83","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamapsychiatry.2022.2996","volume":"79","author":"H Bottemanne","year":"2022","unstructured":"Bottemanne H, Morlaas O, Claret A, Sharot T, Fossati P, Schmidt L. Evaluation of early ketamine effects on belief-updating biases in patients with treatment-resistant depression. JAMA Psychiat. 2022;79(11):1124\u201332. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2996.","journal-title":"JAMA Psychiat"},{"key":"1296_CR84","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jad.2020.11.045","volume":"281","author":"MH Chen","year":"2021","unstructured":"Chen MH, Wu HJ, Li CT, Lin WC, Bai YM, Tsai SJ, et al. Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: post hoc pooled analyses of randomized placebo-controlled and open-label trials. J Affect Disord. 2021;281:865\u201371. https:\/\/doi.org\/10.1016\/j.jad.2020.11.045.","journal-title":"J Affect Disord"},{"key":"1296_CR85","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00406-020-01221-z","volume":"271","author":"X Chen","year":"2021","unstructured":"Chen X, Wang M, Hu Y, Zhan Y, Zhou Y, Zheng W, et al. Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2021;271:431\u20138. https:\/\/doi.org\/10.1007\/s00406-020-01221-z.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"11","key":"1296_CR86","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/da.23193","volume":"38","author":"EJ Daly","year":"2021","unstructured":"Daly EJ, Turkoz I, Salvadore G, Fedgchin M, Ionescu DF, Starr HL, et al. The effect of esketamine in patients with treatment\u2010resistant depression with and without comorbid anxiety symptoms or disorder. Depress Anxiety. 2021;38(11):1120\u201330. https:\/\/doi.org\/10.1002\/da.23193.","journal-title":"Depress Anxiety"},{"key":"1296_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.110126","volume":"105","author":"O Lipsitz","year":"2021","unstructured":"Lipsitz O, McIntyre RS, Rodrigues NB, Kaster TS, Cha DS, Brietzke E, et al. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: results from the Canadian Rapid Treatment Center of Excellence. Prog Neuropsychopharmacol Biol Psychiatry. 2021;105:110126. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110126.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1296_CR88","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jpsychires.2020.08.002","volume":"136","author":"O Lipsitz","year":"2021","unstructured":"Lipsitz O, McIntyre RS, Rodrigues NB, Lee Y, Cha DS, Gill H, et al. Intravenous ketamine for postmenopausal women with treatment-resistant depression: results from the Canadian Rapid Treatment Center of Excellence. J Psychiatr Res. 2021;136:444\u201351. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.08.002.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"1296_CR89","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0269881120978398","volume":"35","author":"AC Lucchese","year":"2021","unstructured":"Lucchese AC, Sarin LM, Magalh\u00e3es EJM, Del Sant LC, Puertas BC, Tuena MA, et al. Repeated subcutaneous esketamine for treatment-resistant depression: impact of the degree of treatment resistance and anxiety comorbidity. J Psychopharmacol. 2021;35(2):142\u20139. https:\/\/doi.org\/10.1177\/0269881120978398.","journal-title":"J Psychopharmacol"},{"key":"1296_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.608499","volume":"12","author":"EJM Magalh\u00e3es","year":"2021","unstructured":"Magalh\u00e3es EJM, Sarin LM, Del Sant LC, Lucchese AC, Nakahira C, Tuena MA, et al. A clinical rationale for assessing the impact of childhood sexual abuse on adjunctive subcutaneous esketamine for treatment-resistant depression. Front Psychiatry. 2021;12:608499. https:\/\/doi.org\/10.3389\/fpsyt.2021.608499.","journal-title":"Front Psychiatry"},{"key":"1296_CR91","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jad.2021.05.090","volume":"292","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Lipsitz O, Lui LM, Rodrigues NB, Lee Y, Ho RC, et al. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? J Affect Disord. 2021;292:714\u20139. https:\/\/doi.org\/10.1016\/j.jad.2021.05.090.","journal-title":"J Affect Disord"},{"issue":"6","key":"1296_CR92","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.clinph.2021.01.030","volume":"132","author":"T Meyer","year":"2021","unstructured":"Meyer T, Brunovsky M, Horacek J, Novak T, Andrashko V, Seifritz E, et al. Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials. Clin Neurophysiol. 2021;132(6):1339\u201346. https:\/\/doi.org\/10.1016\/j.clinph.2021.01.030.","journal-title":"Clin Neurophysiol"},{"issue":"11","key":"1296_CR93","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1007\/s00213-021-05939-z","volume":"238","author":"S Pennybaker","year":"2021","unstructured":"Pennybaker S, Roach BJ, Fryer SL, Badathala A, Wallace AW, Mathalon DH, et al. Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression. Psychopharmacology. 2021;238(11):3229\u201337. https:\/\/doi.org\/10.1007\/s00213-021-05939-z.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1296_CR94","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13400","volume":"31","author":"NB Rodrigues","year":"2021","unstructured":"Rodrigues NB, McIntyre RS, Lipsitz O, Cha DS, Cao B, Lee Y, et al. Do sleep changes mediate the anti\u2010depressive and anti\u2010suicidal response of intravenous ketamine in treatment\u2010resistant depression? J Sleep Res. 2021;31(1):e13400. https:\/\/doi.org\/10.1111\/jsr.13400.","journal-title":"J Sleep Res"},{"key":"1296_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.696170","volume":"12","author":"C Schiweck","year":"2021","unstructured":"Schiweck C, Lutin E, De Raedt W, Cools O, Coppens V, Morrens M, et al. Twenty-four-hour heart rate is a trait but not state marker for depression in a pilot randomized controlled trial with a single infusion of ketamine. Front Psychiatry. 2021;12:696170. https:\/\/doi.org\/10.3389\/fpsyt.2021.696170.","journal-title":"Front Psychiatry"},{"key":"1296_CR96","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s325000","author":"A Wilkowska","year":"2021","unstructured":"Wilkowska A, W\u0142odarczyk A, Ga\u0142uszko-W\u0119gielnik M, Wiglusz MS, Cuba\u0142a WJ. Intravenous ketamine infusions in treatment-resistant bipolar depression: an open-label naturalistic observational study. Neuropsychiatr Dis Treat. 2021. https:\/\/doi.org\/10.2147\/ndt.s325000.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1296_CR97","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-42473\/v2","author":"A W\u0142odarczyk","year":"2021","unstructured":"W\u0142odarczyk A, Cuba\u0142a WJ, W\u0119gielnik-Ga\u0142uszko M, Wiglusz MS. Ketamine treatment safety in treatment-resistant depression with somatic comorbidities: focus on dissociation and psychotic symptomatology. Res Square. 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-42473\/v2.","journal-title":"Res Square."},{"issue":"4","key":"1296_CR98","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ijnp\/pyab084","volume":"25","author":"G Chen","year":"2022","unstructured":"Chen G, Chen L, Zhang Y, Li X, Lane R, Lim P, et al. Relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression. Int J Neuropsychopharmacol. 2022;25(4):269\u201379. https:\/\/doi.org\/10.1093\/ijnp\/pyab084.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1296_CR99","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jad.2022.07.054","volume":"315","author":"KS Chen","year":"2022","unstructured":"Chen KS, Dwivedi Y, Shelton RC. The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder. J Affect Disord. 2022;315:13\u20136. https:\/\/doi.org\/10.1016\/j.jad.2022.07.054.","journal-title":"J Affect Disord"},{"issue":"1","key":"1296_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-03789-3","volume":"22","author":"D Dai","year":"2022","unstructured":"Dai D, Miller C, Valdivia V, Boyle B, Bolton P, Li S, et al. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review. BMC Psychiatry. 2022;22(1):140. https:\/\/doi.org\/10.1186\/s12888-022-03789-3.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1296_CR101","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.22m14491","volume":"84","author":"A Feeney","year":"2022","unstructured":"Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH, et al. Effect of concomitant benzodiazepines on the antidepressant effects of ketamine: findings from the RAPID intravenous ketamine study. J Clin Psychiatry. 2022;84(1):43883. https:\/\/doi.org\/10.4088\/jcp.22m14491.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1296_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2836","volume":"37","author":"AP Jesus\u2010Nunes","year":"2022","unstructured":"Jesus\u2010Nunes AP, Leal GC, Correia\u2010Melo FS, Vieira F, Mello RP, Caliman\u2010Fontes AT, et al. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment\u2010resistant depression. Hum Psychopharmacol Clin Exp. 2022;37(4):e2836. https:\/\/doi.org\/10.1002\/hup.2836.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1296_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.793677","volume":"13","author":"X Lan","year":"2022","unstructured":"Lan X, Zhou Y, Wang C, Li W, Zhang F, Liu H, et al. Pre-treatment pain symptoms influence antidepressant response to ketamine in depressive patients. Front Psychiatry. 2022;13:793677. https:\/\/doi.org\/10.3389\/fpsyt.2022.793677.","journal-title":"Front Psychiatry"},{"issue":"6","key":"1296_CR104","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.21m14336","volume":"83","author":"PA Oliver","year":"2022","unstructured":"Oliver PA, Snyder AD, Feinn R, Malov S, McDiarmid G, Arias AJ. Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation, and generalized anxiety symptoms: a retrospective chart review. J Clin Psychiatry. 2022;83(6):42811. https:\/\/doi.org\/10.4088\/jcp.21m14336.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1296_CR105","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/ijnp\/pyac045","volume":"25","author":"JL Phillips","year":"2022","unstructured":"Phillips JL, Van Geel A, Burhunduli P, Vasudev D, Batten LA, Norris S, et al. Assessment of objective and subjective cognitive function in patients with treatment-resistant depression undergoing repeated ketamine infusions. Int J Neuropsychopharmacol. 2022;25(12):992\u20131002. https:\/\/doi.org\/10.1093\/ijnp\/pyac045.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"1296_CR106","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/jcp.0000000000001524","volume":"42","author":"H Sakurai","year":"2022","unstructured":"Sakurai H, Hoeppner B, Jain F, Foster S, Pedrelli P, Mischoulon D, et al. Use of staging models for treatment-resistant depression is not helpful in predicting nonresponse to acute intravenous ketamine treatment. J Clin Psychopharmacol. 2022;42(2):140\u20135. https:\/\/doi.org\/10.1097\/jcp.0000000000001524.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"1296_CR107","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1177\/02698811231171531","volume":"37","author":"N Chisamore","year":"2023","unstructured":"Chisamore N, Danayan K, Rodrigues NB, Di Vincenzo JD, Meshkat S, Doyle Z, et al. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth. J Psychopharmacol. 2023;37(8):775\u201383. https:\/\/doi.org\/10.1177\/02698811231171531.","journal-title":"J Psychopharmacol"},{"key":"1296_CR108","doi-asserted-by":"publisher","first-page":"115133","DOI":"10.1016\/j.psychres.2023.115133","volume":"323","author":"K Danayan","year":"2023","unstructured":"Danayan K, Chisamore N, Rodrigues NB, Di Vincenzo JD, Meshkat S, Doyle Z, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133. https:\/\/doi.org\/10.1016\/j.psychres.2023.115133.","journal-title":"Psychiatry Res"},{"key":"1296_CR109","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jad.2023.09.030","volume":"342","author":"I Estrade","year":"2023","unstructured":"Estrade I, Petit AC, Sylvestre V, Danon M, Leroy S, Perrain R, et al. Early effects predict trajectories of response to esketamine in treatment-resistant depression. J Affect Disord. 2023;342:166\u201376. https:\/\/doi.org\/10.1016\/j.jad.2023.09.030.","journal-title":"J Affect Disord"},{"key":"1296_CR110","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jad.2022.10.020","volume":"321","author":"MK Jha","year":"2023","unstructured":"Jha MK, Williamson DJ, Magharehabed G, Turkoz I, Daly EJ, Trivedi MH. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability. J Affect Disord. 2023;321:153\u201360. https:\/\/doi.org\/10.1016\/j.jad.2022.10.020.","journal-title":"J Affect Disord"},{"issue":"8","key":"1296_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081164","volume":"16","author":"B Joseph","year":"2023","unstructured":"Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, et al. Efficacy of ketamine with and without lamotrigine in treatment-resistant depression: a preliminary report. Pharmaceuticals Basel. 2023;16(8):1164. https:\/\/doi.org\/10.3390\/ph16081164.","journal-title":"Pharmaceuticals Basel"},{"issue":"3","key":"1296_CR112","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bdi.13296","volume":"25","author":"G Martinotti","year":"2023","unstructured":"Martinotti G, Dell\u2019Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, et al. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disord. 2023;25(3):233\u201344. https:\/\/doi.org\/10.1111\/bdi.13296.","journal-title":"Bipolar Disord"},{"issue":"4","key":"1296_CR113","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00213-023-06324-8","volume":"240","author":"DS Mathai","year":"2023","unstructured":"Mathai DS, Nayak SM, Yaden DB, Garcia-Romeu A. Reconsidering \u201cdissociation\u201d as a predictor of antidepressant efficacy for esketamine. Psychopharmacology. 2023;240(4):827\u201336. https:\/\/doi.org\/10.1007\/s00213-023-06324-8.","journal-title":"Psychopharmacology"},{"key":"1296_CR114","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jad.2022.10.031","volume":"321","author":"B O\u2019Brien","year":"2023","unstructured":"O\u2019Brien B, Lee J, Kim S, Nandra GS, Pannu P, Swann AC, et al. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023;321:140\u20136. https:\/\/doi.org\/10.1016\/j.jad.2022.10.031.","journal-title":"J Affect Disord"},{"key":"1296_CR115","doi-asserted-by":"publisher","first-page":"115378","DOI":"10.1016\/j.psychres.2023.115378","volume":"327","author":"M Pettorruso","year":"2023","unstructured":"Pettorruso M, Guidotti R, d\u2019Andrea G, De Risio L, D\u2019Andrea A, Chiappini S, et al. Predicting outcome with intranasal esketamine treatment: a machine-learning, three-month study in treatment-resistant depression (ESK-LEARNING). Psychiatry Res. 2023;327:115378. https:\/\/doi.org\/10.1016\/j.psychres.2023.115378.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1296_CR116","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.22m14548","volume":"84","author":"B Singh","year":"2023","unstructured":"Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, et al. Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study. J Clin Psychiatry. 2023;84(2):45331. https:\/\/doi.org\/10.4088\/jcp.22m14548.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1296_CR117","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","volume":"26","author":"TP Su","year":"2023","unstructured":"Su TP, Li CT, Lin WC, Wu HJ, Tsai SJ, Bai YM, et al. A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation. Int J Neuropsychopharmacol. 2023;26(5):331\u20139. https:\/\/doi.org\/10.1093\/ijnp\/pyad014.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1296_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115165","volume":"323","author":"I Turkoz","year":"2023","unstructured":"Turkoz I, Nelson JC, Wilkinson ST, Borentain S, Macaluso M, Trivedi MH, et al. Predictors of response and remission in patients with treatment-resistant depression: a post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Res. 2023;323:115165. https:\/\/doi.org\/10.1016\/j.psychres.2023.115165.","journal-title":"Psychiatry Res"},{"issue":"1","key":"1296_CR119","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.23.1097","volume":"22","author":"J Vendrell-Serres","year":"2023","unstructured":"Vendrell-Serres J, Soto-Angona \u00d3, Rodr\u00edguez-Urrutia A, Inzoli B, Gonz\u00e1lez AL, Ramos-Quiroga JA. Treating treatment-resistant depression with esketamine nasal spray when all therapeutic options have been exhausted: clinical experience from a Spanish cohort of expanded use. Clin Psychopharmacol Neurosci. 2023;22(1):159. https:\/\/doi.org\/10.9758\/cpn.23.1097.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1296_CR120","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jad.2023.04.015","volume":"333","author":"A Zavaliangos-Petropulu","year":"2023","unstructured":"Zavaliangos-Petropulu A, McClintock SM, Khalil J, Joshi SH, Taraku B, Al-Sharif NB, et al. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression. J Affect Disord. 2023;333:161\u201371. https:\/\/doi.org\/10.1016\/j.jad.2023.04.015.","journal-title":"J Affect Disord"},{"issue":"4","key":"1296_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsgos.2024.100316","volume":"4","author":"J Aepfelbacher","year":"2024","unstructured":"Aepfelbacher J, Panny B, Price RB. Experiences of awe mediate ketamine\u2019s antidepressant effects: findings from a randomized controlled trial in treatment-resistant depression. Biol Psychiatry Glob Open Sci. 2024;4(4):100316. https:\/\/doi.org\/10.1016\/j.bpsgos.2024.100316.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"1296_CR122","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpsychires.2024.04.008","volume":"174","author":"L Dvorak","year":"2024","unstructured":"Dvorak L, Bloemhof-Bris E, Shelef A, Halperin D, Wexler G, Talmon O, et al. Efficacy of esketamine among patients with treatment resistant depression in a \u2018real world\u2019 health-care setting in Israel. J Psychiatr Res. 2024;174:66\u201372. https:\/\/doi.org\/10.1016\/j.jpsychires.2024.04.008.","journal-title":"J Psychiatr Res"},{"issue":"7","key":"1296_CR123","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/s41591-024-03063-x","volume":"30","author":"P Glue","year":"2024","unstructured":"Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024;30(7):2004\u20139. https:\/\/doi.org\/10.1038\/s41591-024-03063-x.","journal-title":"Nat Med"},{"issue":"1","key":"1296_CR124","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/02698811241267837","volume":"39","author":"L Guti\u00e9rrez-Rojas","year":"2024","unstructured":"Guti\u00e9rrez-Rojas L, Vendrell-Serres J, Ramos-Quiroga JA, Etxeandia-Pradera JI, Aguilar E, De Santiago-D\u00edaz AI, et al. Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment. J Psychopharmacol. 2024;39(1):38\u201348. https:\/\/doi.org\/10.1177\/02698811241267837.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1296_CR125","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17786","volume":"7","author":"MK Jha","year":"2024","unstructured":"Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrough J, et al. Ketamine vs electroconvulsive therapy for treatment-resistant depression: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2417786. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.17786.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1296_CR126","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000658","volume":"32","author":"WC Lin","year":"2024","unstructured":"Lin WC, Su TP, Li CT, Tsai SJ, Tu PC, Bai YM, et al. Current suicide risk, but not lifetime history of attempted suicide, predicts treatment response to low-dose ketamine infusion: post hoc analysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. Exp Clin Psychopharmacol. 2024;32(1):84. https:\/\/doi.org\/10.1037\/pha0000658.","journal-title":"Exp Clin Psychopharmacol"},{"key":"1296_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115858","volume":"335","author":"EA Miller","year":"2024","unstructured":"Miller EA, Afshar HT, Mishra J, McIntyre RS, Ramanathan D. Predicting non-response to ketamine for depression: an exploratory symptom-level analysis of real-world data among military veterans. Psychiatry Res. 2024;335:115858. https:\/\/doi.org\/10.1016\/j.psychres.2024.115858.","journal-title":"Psychiatry Res"},{"issue":"16","key":"1296_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164767","volume":"13","author":"L Moccia","year":"2024","unstructured":"Moccia L, Bartolucci G, Pepe M, Marcelli I, Grisoni F, Brugnami A, et al. Heart rate variability as a potential predictor of response to intranasal esketamine in patients with treatment-resistant depression: a preliminary report. J Clin Med. 2024;13(16):4767. https:\/\/doi.org\/10.3390\/jcm13164767.","journal-title":"J Clin Med"},{"issue":"12","key":"1296_CR129","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/pcn.13734","volume":"78","author":"Y Ohtani","year":"2024","unstructured":"Ohtani Y, Tani H, Nomoto-Takahashi K, Yatomi T, Yonezawa K, Tomiyama S, et al. Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial. Psychiatry Clin Neurosci. 2024;78(12):765\u201375. https:\/\/doi.org\/10.1111\/pcn.13734.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1296_CR130","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jad.2023.12.033","volume":"348","author":"SV Parikh","year":"2024","unstructured":"Parikh SV, Vande Voort JL, Yocum AK, Achtyes E, Goes FS, Nykamp L, et al. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression. J Affect Disord. 2024;348:143\u201351. https:\/\/doi.org\/10.1016\/j.jad.2023.12.033.","journal-title":"J Affect Disord"},{"key":"1296_CR131","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jad.2024.01.003","volume":"349","author":"L Patarroyo-Rodriguez","year":"2024","unstructured":"Patarroyo-Rodriguez L, Pazdernik V, Vande Voort JL, Kung S, et al. Hypersomnia as a predictor of response to intravenous ketamine\/intranasal esketamine in treatment resistant depression. J Affect Disord. 2024;349:272\u20136. https:\/\/doi.org\/10.1016\/j.jad.2024.01.003.","journal-title":"J Affect Disord"},{"key":"1296_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmip.2024.100119","volume":"43","author":"EM Peters","year":"2024","unstructured":"Peters EM, Halpape K, Cheveldae I, Jacobson P, Wanson A. Predictors of response to intranasal ketamine in patients hospitalized for treatment-resistant depression. Pers Med Psychiatry. 2024;43:100119. https:\/\/doi.org\/10.1016\/j.pmip.2024.100119.","journal-title":"Pers Med Psychiatry"},{"issue":"4","key":"1296_CR133","doi-asserted-by":"publisher","first-page":"pyae017","DOI":"10.1093\/ijnp\/pyae017","volume":"27","author":"S Sajid","year":"2024","unstructured":"Sajid S, Galfalvy HC, Keilp JG, Burke AK, Mann JJ, Grunebaum MF. Acute dissociation and ketamine\u2019s antidepressant and anti-suicidal ideation effects in a midazolam-controlled trial. Int J Neuropsychopharmacol. 2024;27(4):pyae017. https:\/\/doi.org\/10.1093\/ijnp\/pyae017.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1296_CR134","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2024.18","volume":"37","author":"K Sandstr\u00f6m","year":"2024","unstructured":"Sandstr\u00f6m K, Kampman O, Asellus P. A retrospective analysis of iv ketamine outcome on hospitalisations in an unselected psychiatric sample. Acta Neuropsychiatr. 2024;37:e13. https:\/\/doi.org\/10.1017\/neu.2024.18.","journal-title":"Acta Neuropsychiatr"},{"key":"1296_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115829","volume":"335","author":"B Singh","year":"2024","unstructured":"Singh B, Parikh SV, Vande Voort JL, Pazdernik VK, Achtyes ED, Goes FS, et al. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: the Bio-K multicenter trial. Psychiatry Res. 2024;335:115829. https:\/\/doi.org\/10.1016\/j.psychres.2024.115829.","journal-title":"Psychiatry Res"},{"key":"1296_CR136","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jad.2024.01.262","volume":"351","author":"B Singh","year":"2024","unstructured":"Singh B, Vande Voort JL, Pazdernik VK, Frye MA, Kung S. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine\/esketamine. J Affect Disord. 2024;351:534\u201340. https:\/\/doi.org\/10.1016\/j.jad.2024.01.262.","journal-title":"J Affect Disord"},{"key":"1296_CR137","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jad.2024.01.165","volume":"350","author":"S Vestring","year":"2024","unstructured":"Vestring S, Galuba V, Kern E, Voita S, Berens F, Nasiri D, et al. Ketamine in multiple treatment-resistant depressed inpatients: a naturalistic cohort study. J Affect Disord. 2024;350:895\u20139. https:\/\/doi.org\/10.1016\/j.jad.2024.01.165.","journal-title":"J Affect Disord"},{"issue":"1","key":"1296_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03027-2","volume":"14","author":"C Wang","year":"2024","unstructured":"Wang C, Lan X, Liu W, Zhan Y, Zheng W, Chen X, et al. Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression. Transl Psychiatry. 2024;14(1):324. https:\/\/doi.org\/10.1038\/s41398-024-03027-2.","journal-title":"Transl Psychiatry"},{"issue":"01","key":"1296_CR139","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/a-2179-8884","volume":"57","author":"K Yonezawa","year":"2024","unstructured":"Yonezawa K, Uchida H, Yatomi T, Ohtani Y, Nomoto-Takahashi K, Nakajima S, et al. Factors associated with antidepressant effects of ketamine: a reanalysis of double-blind randomized placebo-controlled trial of intravenous ketamine for treatment-resistant depression. Pharmacopsychiatry. 2024;57(01):35\u201340. https:\/\/doi.org\/10.1055\/a-2179-8884.","journal-title":"Pharmacopsychiatry"},{"key":"1296_CR140","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jad.2025.03.198","volume":"381","author":"M Ansari","year":"2025","unstructured":"Ansari M, Rhee TG, Santucci MC, Nikayin S. Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data. J Affect Disord. 2025;381:22\u20138. https:\/\/doi.org\/10.1016\/j.jad.2025.03.198.","journal-title":"J Affect Disord"},{"key":"1296_CR141","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jad.2025.04.117","volume":"383","author":"S Cavalcanti","year":"2025","unstructured":"Cavalcanti S, Pazdernik VK, Vande Voort JL, Kung S, Singh B. Baseline perceived stress as a predictor of ketamine\/esketamine treatment response in treatment-resistant depression. J Affect Disord. 2025;383:283\u20139. https:\/\/doi.org\/10.1016\/j.jad.2025.04.117.","journal-title":"J Affect Disord"},{"issue":"1","key":"1296_CR142","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2025.10096","volume":"68","author":"I Conejero","year":"2025","unstructured":"Conejero I, Garc\u00eda RA, Porras-Segovia A, Beltr\u00e1n AMDG, L\u00f3pez SB, Di Stasio E, et al. Esketamine use in real-world clinical practice in patients with treatment-resistant depression. Eur Psychiatry. 2025;68(1):e158. https:\/\/doi.org\/10.1192\/j.eurpsy.2025.10096.","journal-title":"Eur Psychiatry"},{"key":"1296_CR143","doi-asserted-by":"publisher","DOI":"10.47626\/2237-6089-2022-0593","volume":"47","author":"MV Echegaray","year":"2025","unstructured":"Echegaray MV, Mello RP, Magnavita GM, Leal GC, Correia-Melo FS, Jesus-Nunes AP, et al. Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine or esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trial. Trends Psychiatry Psychother. 2025;47:e20220593. https:\/\/doi.org\/10.47626\/2237-6089-2022-0593.","journal-title":"Trends Psychiatry Psychother"},{"issue":"11","key":"1296_CR144","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40263-025-01210-7","volume":"39","author":"R Guglielmo","year":"2025","unstructured":"Guglielmo R, Marino M, Briasco E, Cavanna E, Inuggi A, Schiavon F, et al. Predictors of esketamine response in treatment-resistant depression: the role of temperament and cumulative treatment resistance. CNS Drugs. 2025;39(11):1187\u201391. https:\/\/doi.org\/10.1007\/s40263-025-01210-7.","journal-title":"CNS Drugs"},{"key":"1296_CR145","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13812","author":"DE Johnson","year":"2025","unstructured":"Johnson DE, Rodrigues NB, Mansur RB, McIntyre RS, Rosenblat JD. The influence of childhood trauma on the real\u2010world effectiveness of ketamine in adults with treatment\u2010resistant depression. Acta Psychiatr Scand. 2025. https:\/\/doi.org\/10.1111\/acps.13812.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1296_CR146","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.70038","volume":"45","author":"Z Kachlik","year":"2025","unstructured":"Kachlik Z, Cuba\u0142a WJ, Walaszek M, Pastuszak M, Pastuszak K, Kwa\u015bny A. Nonresponse to ketamine in treatment\u2010resistant bipolar depression. Neuropsychopharmacol Rep. 2025;45(3):e70038. https:\/\/doi.org\/10.1002\/npr2.70038.","journal-title":"Neuropsychopharmacol Rep"},{"key":"1296_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120231","volume":"392","author":"M Olivola","year":"2026","unstructured":"Olivola M, Mazzoni F, Tarantino B, Guffanti A, Marcatili M, Motta FL, et al. Mentalization and emotional-cognitive rigidity as predictors of esketamine\u2019s effects on treatment-resistant depression: findings from a prospective observational study. J Affect Disord. 2026;392:120231. https:\/\/doi.org\/10.1016\/j.jad.2025.120231.","journal-title":"J Affect Disord"},{"key":"1296_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119414","volume":"385","author":"BK Penaluna","year":"2025","unstructured":"Penaluna BK, Vande Voort JL, Bobo WV, Pazdernik V, Achtyes ED, Goes FS, et al. Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: the bio-K multicenter trial. J Affect Disord. 2025;385:119414. https:\/\/doi.org\/10.1016\/j.jad.2025.119414.","journal-title":"J Affect Disord"},{"key":"1296_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116411","volume":"347","author":"G Sanacora","year":"2025","unstructured":"Sanacora G, Barnett BS, Hu B, Goes FS, Mathew SJ, Murrough JW, et al. Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: an ELEKT-D trial secondary analysis. Psychiatry Res. 2025;347:116411. https:\/\/doi.org\/10.1016\/j.psychres.2025.116411.","journal-title":"Psychiatry Res"},{"key":"1296_CR150","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06896-7","author":"MC Santucci","year":"2025","unstructured":"Santucci MC, Katz RB, Pittman B, Nikayin S, Wilkinson ST. Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine or esketamine. Psychopharmacology. 2025. https:\/\/doi.org\/10.1007\/s00213-025-06896-7. (online ahead of print).","journal-title":"Psychopharmacology"},{"key":"1296_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1498952","volume":"16","author":"JQ Tan","year":"2025","unstructured":"Tan JQ, Gu LM, Zhou YL, Wang CY, Lan XF, Zheng W, et al. Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression. Front Psychiatry. 2025;16:1498952. https:\/\/doi.org\/10.3389\/fpsyt.2025.1498952.","journal-title":"Front Psychiatry"},{"issue":"4","key":"1296_CR152","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s43440-025-00730-9","volume":"77","author":"M Walaszek","year":"2025","unstructured":"Walaszek M, Cuba\u0142a WJ, Kachlik Z, Pastuszak M, Pastuszak K, Kwa\u015bny A. Non-response to short-term ketamine use for treatment-resistant depression. Pharmacol Rep. 2025;77(4):1126\u201333. https:\/\/doi.org\/10.1007\/s43440-025-00730-9.","journal-title":"Pharmacol Rep"},{"issue":"4","key":"1296_CR153","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1176\/appi.focus.22020004","volume":"178","author":"JB Dwyer","year":"2021","unstructured":"Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry. 2021;178(4):352\u201362. https:\/\/doi.org\/10.1176\/appi.focus.22020004.","journal-title":"Am J Psychiatry"},{"key":"1296_CR154","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jpsychires.2021.02.058","volume":"137","author":"JD Di Vincenzo","year":"2021","unstructured":"Di Vincenzo JD, Siegel A, Lipsitz O, Ho R, Teopiz KM, Ng J, et al. The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: a systematic review. J Psychiatr Res. 2021;137:232\u201341. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.02.058.","journal-title":"J Psychiatr Res"},{"issue":"12","key":"1296_CR155","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11920-017-0855-x","volume":"19","author":"C Medeiros da Frota Ribeiro","year":"2017","unstructured":"Medeiros da Frota Ribeiro C, Riva-Posse P. Use of ketamine in elderly patients with treatment-resistant depression. Curr Psychiatry Tep. 2017;19(12):107. https:\/\/doi.org\/10.1007\/s11920-017-0855-x.","journal-title":"Curr Psychiatry Tep."},{"issue":"6-7","key":"1296_CR156","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/09540261.2025.2581238","volume":"37","author":"IP Magalh\u00e3es","year":"2025","unstructured":"Magalh\u00e3es IP, Lopes DN, Amato I, Ribeiro MV, Luz R, Lacerda AL, et al. Ketamine for major depression in adolescents: a systematic review and meta-analysis of efficacy and safety. Int Rev Psychiatry. 2025;37(6\u20137):731\u201340. https:\/\/doi.org\/10.1080\/09540261.2025.2581238.","journal-title":"Int Rev Psychiatry"},{"key":"1296_CR157","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jpsychires.2023.01.043","volume":"159","author":"JR Strawn","year":"2023","unstructured":"Strawn JR, Mills JA, Suresh V, Mayes T, Gentry MT, Trivedi M, et al. The impact of age on antidepressant response: a mega-analysis of individuals with major depressive disorder. J Psychiatr Res. 2023;159:266\u201373. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.01.043.","journal-title":"J Psychiatr Res"},{"issue":"10","key":"1296_CR158","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4088\/jcp.14r09528","volume":"76","author":"AU Haq","year":"2015","unstructured":"Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015;76(10):374\u201384. https:\/\/doi.org\/10.4088\/jcp.14r09528.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1296_CR159","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1192\/bjp.2017.28","volume":"212","author":"L Van Diermen","year":"2018","unstructured":"Van Diermen L, Van Den Ameele S, Kamperman AM, Sabbe BC, Vermeulen T, Schrijvers D, et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br J Psychiatry. 2018;212(2):71\u201380. https:\/\/doi.org\/10.1192\/bjp.2017.28.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"1296_CR160","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1017\/s1041610224000462","volume":"36","author":"MK Leuchter","year":"2024","unstructured":"Leuchter MK, Citrenbaum C, Wilson AC, Tibbe TD, Jackson NJ, Krantz DE, et al. The effect of older age on outcomes of rTMS treatment for treatment-resistant depression. Int Psychogeriatr. 2024;36(11):1070\u20135. https:\/\/doi.org\/10.1017\/s1041610224000462.","journal-title":"Int Psychogeriatr"},{"issue":"6","key":"1296_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060907","volume":"12","author":"M Romanescu","year":"2022","unstructured":"Romanescu M, Buda V, Lombrea A, Andor M, Ledeti I, Suciu M, et al. Sex-related differences in pharmacological response to CNS drugs: a narrative review. J Pers Med. 2022;12(6):907. https:\/\/doi.org\/10.3390\/jpm12060907.","journal-title":"J Pers Med"},{"issue":"6","key":"1296_CR162","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/ijnp\/pyac017","volume":"25","author":"C Moderie","year":"2022","unstructured":"Moderie C, Nu\u00f1ez N, Fielding A, Comai S, Gobbi G. Sex differences in responses to antidepressant augmentations in treatment-resistant depression. Int J Neuropsychopharmacol. 2022;25(6):479\u201388. https:\/\/doi.org\/10.1093\/ijnp\/pyac017.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1296_CR163","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.yfrne.2018.05.003","volume":"50","author":"AV Williams","year":"2018","unstructured":"Williams AV, Trainor BC. The impact of sex as a biological variable in the search for novel antidepressants. Front Neuroendocrinol. 2018;50:107\u201317. https:\/\/doi.org\/10.1016\/j.yfrne.2018.05.003.","journal-title":"Front Neuroendocrinol"},{"key":"1296_CR164","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","volume":"136","author":"E Dakwar","year":"2014","unstructured":"Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.12.019.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1296_CR165","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00406-024-01770-7","volume":"275","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K. Are \u201cmystical experiences\u201d essential for antidepressant actions of ketamine and the classic psychedelics? Eur Arch Psychiatry Clin Neurosci. 2025;275(5):1333\u201346. https:\/\/doi.org\/10.1007\/s00406-024-01770-7.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1296_CR166","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jad.2020.01.113","volume":"267","author":"S Puzhko","year":"2020","unstructured":"Puzhko S, Aboushawareb SA, Kudrina I, Schuster T, Barnett TA, Renoux C, et al. Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder. J Affect Disord. 2020;267:153\u201370. https:\/\/doi.org\/10.1016\/j.jad.2020.01.113.","journal-title":"J Affect Disord"},{"issue":"1","key":"1296_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010080","volume":"17","author":"YS Woo","year":"2016","unstructured":"Woo YS, Seo HJ, McIntyre RS, Bahk WM. Obesity and its potential effects on antidepressant treatment outcomes in patients with depressive disorders: a literature review. Int J Mol Sci. 2016;17(1):80. https:\/\/doi.org\/10.3390\/ijms17010080.","journal-title":"Int J Mol Sci"},{"key":"1296_CR168","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jad.2019.06.067","volume":"256","author":"N Dreimueller","year":"2019","unstructured":"Dreimueller N, Lieb K, Tadi\u0107 A, Engelmann J, Wollschlaeger D, Wagner S. Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response. J Affect Disord. 2019;256:524\u201331. https:\/\/doi.org\/10.1016\/j.jad.2019.06.067.","journal-title":"J Affect Disord"},{"key":"1296_CR169","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jad.2018.02.089","volume":"234","author":"MK Jha","year":"2018","unstructured":"Jha MK, Wakhlu S, Dronamraju N, Minhajuddin A, Greer TL, Trivedi MH. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: findings from CO-MED trial. J Affect Disord. 2018;234:34\u20137. https:\/\/doi.org\/10.1016\/j.jad.2018.02.089.","journal-title":"J Affect Disord"},{"issue":"7","key":"1296_CR170","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1089\/cap.2012.0095","volume":"23","author":"B Mansoor","year":"2013","unstructured":"Mansoor B, Rengasamy M, Hilton R, Porta G, He J, Spirito A, et al. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. J Child Adolesc Psychopharmacol. 2013;23(7):458\u201367. https:\/\/doi.org\/10.1089\/cap.2012.0095.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1296_CR171","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jad.2020.11.059","volume":"281","author":"L Xiao","year":"2021","unstructured":"Xiao L, Zhou J, Galling B, Chen RS, Wang G. The association of body mass index (BMI) with treatment outcomes in patients with major depressive disorder. J Affect Disord. 2021;281:799\u2013804. https:\/\/doi.org\/10.1016\/j.jad.2020.11.059.","journal-title":"J Affect Disord"},{"key":"1296_CR172","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jad.2023.05.042","volume":"335","author":"C Kraus","year":"2023","unstructured":"Kraus C, Kautzky A, Watzal V, Gramser A, Kadriu B, Deng ZD, et al. Body mass index and clinical outcomes in individuals with major depressive disorder: findings from the GSRD European Multicenter Database. J Affect Disord. 2023;335:349\u201357. https:\/\/doi.org\/10.1016\/j.jad.2023.05.042.","journal-title":"J Affect Disord"},{"key":"1296_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197775","volume":"14","author":"P Ninla-Aesong","year":"2023","unstructured":"Ninla-Aesong P, Puangsri P, Kietdumrongwong P, Jongkrijak H, Noipha K. Being overweight and obese increases suicide risk, the severity of depression, and the inflammatory response in adolescents with major depressive disorders. Front Immunol. 2023;14:1197775. https:\/\/doi.org\/10.3389\/fimmu.2023.1197775.","journal-title":"Front Immunol"},{"issue":"3","key":"1296_CR174","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/070674371005500303","volume":"55","author":"M Sinyor","year":"2010","unstructured":"Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR* D) trial: a review. Can J Psychiatry. 2010;55(3):126\u201335. https:\/\/doi.org\/10.1177\/070674371005500303.","journal-title":"Can J Psychiatry"},{"issue":"6","key":"1296_CR175","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/acps.13550","volume":"147","author":"JJE Rovers","year":"2023","unstructured":"Rovers JJE, Vissers P, Loef D, van Waarde JA, Verdijk JPAJ, Broekman BFP, et al. The impact of treatment resistance on outcome and course of electroconvulsive therapy in major depressive disorder. Acta Psychiatr Scand. 2023;147(6):570\u201380. https:\/\/doi.org\/10.1111\/acps.13550.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"1296_CR176","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/da.22862","volume":"36","author":"NS Philip","year":"2019","unstructured":"Philip NS, Leuchter AF, Cook IA, Massaro J, Goethe JW, Carpenter LL. Predictors of response to synchronized transcranial magnetic stimulation for major depressive disorder. Depress Anxiety. 2019;36(3):278\u201385. https:\/\/doi.org\/10.1002\/da.22862.","journal-title":"Depress Anxiety"},{"key":"1296_CR177","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1989-z","volume":"19","author":"J Voigt","year":"2019","unstructured":"Voigt J, Carpenter L, Leuchter A. A systematic literature review of the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in non-treatment resistant patients with major depressive disorder. BMC Psychiatry. 2019;19:111. https:\/\/doi.org\/10.1186\/s12888-018-1989-z.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1296_CR178","doi-asserted-by":"publisher","first-page":"25m03939","DOI":"10.4088\/pcc.25m03939","volume":"27","author":"SB VanBronkhorst","year":"2025","unstructured":"VanBronkhorst SB, Keller JJ, Edwards EM, Saleem AA, Evans DL, Achtyes E, et al. Depression remission and response rates and anxiety response as a predictor of depression response in a community electroconvulsive therapy clinic. Prim Care Companion CNS Disord. 2025;27(4):25m03939. https:\/\/doi.org\/10.4088\/pcc.25m03939.","journal-title":"Prim Care Companion CNS Disord."},{"issue":"7","key":"1296_CR179","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1654","volume":"10","author":"Y Ma","year":"2020","unstructured":"Ma Y, Rosenheck R, Ye B, Fan N, He H. Effectiveness of electroconvulsive therapy in patients with \u201cless treatment\u2010resistant\u201d depression by the Maudsley Staging Model. Brain Behav. 2020;10(7):e01654. https:\/\/doi.org\/10.1002\/brb3.1654.","journal-title":"Brain Behav"},{"key":"1296_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106524","volume":"152","author":"A Hochschild","year":"2021","unstructured":"Hochschild A, Grunebaum MF, Mann JJ. The rapid anti-suicidal ideation effect of ketamine: a systematic review. Prev Med. 2021;152:106524. https:\/\/doi.org\/10.1016\/j.ypmed.2021.106524.","journal-title":"Prev Med"},{"key":"1296_CR181","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067194","volume":"376","author":"M Abbar","year":"2022","unstructured":"Abbar M, Demattei C, El-Hage W, Llorca PM, Samalin L, Demaricourt P, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022;376:e067194. https:\/\/doi.org\/10.1136\/bmj-2021-067194.","journal-title":"BMJ"},{"issue":"1","key":"1296_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02973-1","volume":"14","author":"Z Shen","year":"2024","unstructured":"Shen Z, Gao D, Lv X, Wang H, Yue W. A meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry. 2024;14(1):248. https:\/\/doi.org\/10.1038\/s41398-024-02973-1.","journal-title":"Transl Psychiatry"},{"key":"1296_CR183","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","volume":"58","author":"ED Ballard","year":"2014","unstructured":"Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161\u20136. https:\/\/doi.org\/10.1016\/j.jpsychires.2014.07.027.","journal-title":"J Psychiatr Res"},{"issue":"3","key":"1296_CR184","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157\u201364. https:\/\/doi.org\/10.2174\/1874473708666150107121331.","journal-title":"Curr Drug Abuse Rev"},{"key":"1296_CR185","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.841648","volume":"13","author":"DEW McCulloch","year":"2022","unstructured":"McCulloch DEW, Grzywacz MZ, Madsen MK, Jensen PS, Ozenne B, Armand S, et al. Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report. Front Pharmacol. 2022;13:841648. https:\/\/doi.org\/10.3389\/fphar.2022.841648.","journal-title":"Front Pharmacol"},{"key":"1296_CR186","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.917199","volume":"13","author":"K Ko","year":"2022","unstructured":"Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Front Psychiatry. 2022;13:917199. https:\/\/doi.org\/10.3389\/fpsyt.2022.917199.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1296_CR187","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1556\/2054.2023.00243","volume":"7","author":"S Kangaslampi","year":"2023","unstructured":"Kangaslampi S. Association between mystical-type experiences under psychedelics and improvements in well-being or mental health: a comprehensive review of the evidence. J Psychedelic Stud. 2023;7(1):18\u201328. https:\/\/doi.org\/10.1556\/2054.2023.00243.","journal-title":"J Psychedelic Stud"},{"issue":"7","key":"1296_CR188","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","volume":"174","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry. 2017;174(7):695\u20136. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17020239.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1296_CR189","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/00048674231203898","volume":"58","author":"A Rodgers","year":"2023","unstructured":"Rodgers A, Bahceci D, Davey CG, Chatterton ML, Glozier N, Hopwood M, et al. Ensuring the affordable becomes accessible: lessons from ketamine, a new treatment for severe depression. Aust N Z J Psychiatry. 2023;58(2):109\u201316. https:\/\/doi.org\/10.1177\/00048674231203898.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"1296_CR190","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1176\/appi.ajp.2011.11020335","volume":"169","author":"V Nanni","year":"2012","unstructured":"Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry. 2012;169(2):141\u201351. https:\/\/doi.org\/10.1176\/appi.ajp.2011.11020335.","journal-title":"Am J Psychiatry"},{"key":"1296_CR191","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jad.2022.09.153","volume":"320","author":"E Ng","year":"2023","unstructured":"Ng E, Wong EH, Lipsman N, Nestor SM, Giacobbe P. Adverse childhood experiences and repetitive transcranial magnetic stimulation outcomes for depression. J Affect Disord. 2023;320:716\u201324. https:\/\/doi.org\/10.1016\/j.jad.2022.09.153.","journal-title":"J Affect Disord"},{"key":"1296_CR192","doi-asserted-by":"publisher","DOI":"10.1017\/s2045796021000810","volume":"31","author":"X Sun","year":"2022","unstructured":"Sun X, Liu B, Liu S, Wu DJ, Wang J, Qian Y, et al. Sleep disturbance and psychiatric disorders: a bidirectional Mendelian randomisation study. Epidemiol Psychiatr Sci. 2022;31:e26. https:\/\/doi.org\/10.1017\/s2045796021000810.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"1296_CR193","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.559272","volume":"11","author":"A Reddy","year":"2020","unstructured":"Reddy A, Thootkur M, Li L. Association between major depressive disorder and sleep disturbances through inflammation in adolescents. Front Psychiatry. 2020;11:559272. https:\/\/doi.org\/10.3389\/fpsyt.2020.559272.","journal-title":"Front Psychiatry"},{"key":"1296_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2022.103228","volume":"76","author":"RF Chen","year":"2022","unstructured":"Chen RF, Cai Y, Zhu ZH, Hou WL, Chen P, Wang J, et al. Sleep disorder as a clinical risk factor of major depression: associated with cognitive impairment. Asian J Psychiatry. 2022;76:103228. https:\/\/doi.org\/10.1016\/j.ajp.2022.103228.","journal-title":"Asian J Psychiatry"},{"issue":"4","key":"1296_CR195","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/02698811241238284","volume":"38","author":"NB Rodrigues","year":"2024","unstructured":"Rodrigues NB, Chen-Li D, Di Vincenzo JD, Juneja A, Pinder BD, McIntyre RS, et al. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression. J Psychopharmacol. 2024;38(4):375\u201381. https:\/\/doi.org\/10.1177\/02698811241238284.","journal-title":"J Psychopharmacol"},{"key":"1296_CR196","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jad.2022.12.021","volume":"323","author":"S Meshkat","year":"2023","unstructured":"Meshkat S, Ho RC, Cao B, Teopiz KM, Rosenblat JD, Rhee TG, et al. Biomarkers of ketamine\u2019s antidepressant effect: an umbrella review. J Affect Disord. 2023;323:598\u2013606. https:\/\/doi.org\/10.1016\/j.jad.2022.12.021.","journal-title":"J Affect Disord"},{"issue":"1","key":"1296_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66784-2","volume":"10","author":"SF Husain","year":"2020","unstructured":"Husain SF, Yu R, Tang TB, Tam WW, Tran B, Quek TT, et al. Validating a functional near-infrared spectroscopy diagnostic paradigm for major depressive disorder. Sci Rep. 2020;10(1):9740. https:\/\/doi.org\/10.1038\/s41598-020-66784-2.","journal-title":"Sci Rep"},{"issue":"1","key":"1296_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03224-7","volume":"15","author":"CSH Ho","year":"2025","unstructured":"Ho CSH, Wang J, Tay GWN, Ho R, Lin H, Li Z, et al. Application of functional near-infrared spectroscopy and machine learning to predict treatment response after six months in major depressive disorder. Transl Psychiatry. 2025;15(1):7. https:\/\/doi.org\/10.1038\/s41398-025-03224-7.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1296_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38258-8","volume":"13","author":"A Castillo","year":"2023","unstructured":"Castillo A, Dubois J, Field RM, Fishburn F, Gundran A, Ho WC, et al. Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS. Sci Rep. 2023;13(1):11665. https:\/\/doi.org\/10.1038\/s41598-023-38258-8.","journal-title":"Sci Rep"},{"issue":"3","key":"1296_CR200","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2307\/2531989","volume":"43","author":"SJ Pocock","year":"1987","unstructured":"Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics. 1987;43(3):487\u201398. https:\/\/doi.org\/10.2307\/2531989.","journal-title":"Biometrics"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01296-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:47:17Z","timestamp":1782380837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01296-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":200,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01296-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sean M. Nestor has received research support from Brain Canada, CIHR, the Brain and Behaviour Research Foundation, and the Tory Trauma Program at Sunnybrook Health Sciences Centre. Muhammad Ishrat Husain receives research support from CIHR, CAMH Foundation, and the University of Toronto. He leads contracted research for COMPASS Pathways Limited and has provided consultancy to Mindset Pharma, Neurocentrx, and Otsuka Pharmaceuticals. Fahad Alam has received research grants from PSI and Sunnybrook AFP. He is the co-founder of the Ontario Ketamine and Infusion Clinic. Peter Giacobbe has received grants in the area from CIHR and the PSI Foundation. He receives salary support from the Kerr Chair in Interventional Psychiatry. None of these affiliations had any bearing on their involvement in this publication. Omer A. Syed, Valentyn Sobolenko, and Nir Lipsman have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"OAS and PG conceived the idea; OAS and VS were responsible for the literature search, article screening, and data extraction; OAS conducted the data analysis and wrote the initial draft; and OAS, VS, SMN, MIH, NL, FA and PG critically revised the article. All authors have read and approved the final version of the manuscript, and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}